237 related articles for article (PubMed ID: 17654661)
21. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
22. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
[TBL] [Abstract][Full Text] [Related]
23. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
[TBL] [Abstract][Full Text] [Related]
24. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
25. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
26. [New insights into hypereosinophilic syndromes].
Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
[TBL] [Abstract][Full Text] [Related]
27. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
28. Myeloproliferative hypereosinophilic syndrome presenting as cardiac failure and response to imatinib.
Desai N; Morkhandikar S; Sahay R; Jijina F; Patil P
Am J Ther; 2014; 21(2):e35-7. PubMed ID: 24603276
[TBL] [Abstract][Full Text] [Related]
29. Novel therapies for hypereosinophilic syndromes.
Antoniu SA
Neth J Med; 2010 Aug; 68(1):304-10. PubMed ID: 20739727
[TBL] [Abstract][Full Text] [Related]
30. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
Roufosse F; Goldman M; Cogan E
Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate.
Sun CY; Hu Y; Chu ZB; Guo T; He J
Int J Hematol; 2009 Jan; 89(1):66-70. PubMed ID: 19096755
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of hypereosinophilia].
Charlanne H; Prin L
Presse Med; 2006 Jan; 35(1 Pt 2):167-72. PubMed ID: 16462681
[TBL] [Abstract][Full Text] [Related]
33. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
[TBL] [Abstract][Full Text] [Related]
35. Hypereosinophilic syndrome: diagnosis and treatment.
Peros-Golubicić T; Smojver-Jezek S
Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
[TBL] [Abstract][Full Text] [Related]
36. Modern diagnosis and treatment of primary eosinophilia.
Tefferi A
Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
[TBL] [Abstract][Full Text] [Related]
37. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
38. Novel approaches to therapy of hypereosinophilic syndromes.
Simon HU; Cools J
Immunol Allergy Clin North Am; 2007 Aug; 27(3):519-27. PubMed ID: 17868862
[TBL] [Abstract][Full Text] [Related]
39. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
Yamada Y; Cancelas JA; Rothenberg ME
Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
[TBL] [Abstract][Full Text] [Related]
40. A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib.
Kobayashi M; Kubota T; Uemura Y; Taguchi H
Respirology; 2009 Mar; 14(2):302-4. PubMed ID: 19192229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
